Posluma (flotufolastat F 18) received the U.S. Food and Drug Administration’s approval in May 2023.

According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.

Clinicians only want the information they need to make treatment decisions, rather than advice on what actions they should take, the survey found. 

The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.

The findings support adopting F-18 DCFPyL PET/CT as the standard of care for prostate cancer staging, authors of a new Scientific Reports paper concluded.

Rather than administering radiolabeled glucose for exams, imagers give patients a small amount of a harmless glucose solution that is said to be equivalent to a can of a carbonated drink.

Difficulty obtaining PET/CT scans was reported by 55% of respondents, with 21% citing this as the greatest barrier in treating classic Hodgkin lymphoma.

Abnormalities of the thalamus could be to blame for persistent symptoms in the months following a concussion, according to new research.